A clinical trial update for mazdutide, also known as IBI362, was recorded on October 20, 2026. The study, titled "A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)," is registered under identifier NCT06937749. This is a Phase 2 trial evaluating mazdutide in participants with metabolic dysfunction-associated steatohepatitis. The trial status is currently listed as active, not recruiting. This designation means the study is ongoing but is no longer enrolling new participants at this time. No results or outcome data have been reported as part of this update. Mazdutide remains classified as an unapproved compound under research investigation. This status update reflects only the trial's recruitment stage and does not indicate whether any findings have been generated or published. Readers tracking this study should note that further updates may follow as the trial progresses through its stated phase. For additional background on mazdutide, including its general research classification and development context, readers can consult the compound overview.
Mazdutide Phase 2 MASH Trial Status Updated to Active, Not Recruiting
See the full mazdutide overview
Source: https://clinicaltrials.gov/study/NCT06937749